Trial Profile
Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Sep 2022
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms NEPTUNES
- 28 Jun 2022 The protocol was amended to add a new cohort of patients receiving Nivolumab 3 mg/kg and ipilimumab 1 mg/kg every three weeks for a maximum of 4 doses with a 3 week gap after last combination dose, according to ClinicalTrials.gov record. Accordingly, the patient number was changed to 380.
- 28 Jun 2022 Planned End Date changed from 1 Jul 2025 to 1 Jun 2027.
- 28 Jun 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Aug 2022.